Find Clinical Trials

Inclusion Criteria: A. Adults with hormone receptor-positive (HR+) early breast cancer were confirmed. B. At least 18 years old at the time of signing the informed consent. C. Candidates for adjuvant endocrine therapy in combination with Abemaciclib (either NHI-reimbursed or self-funded), as determined by the primary treating physician. Prior chemotherapy requirement: Must have completed prior adjuvant chemotherapy at least 21 days before enrollment. All chemotherapy-related toxicities (except alopecia or Grade 2 peripheral neuropathy) must have resolved to ≤ Grade 1. D. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. E. Adequate bone marrow function as defined by: 1. Absolute Neutrophil Count (ANC) ≥ 1,500/μL without G-CSF support within 14 days of enrollment. 2. Platelet count ≥ 100,000/μL. 3. Hemoglobin ≥ 8.0 g/dL (red blood cell transfusion is permitted prior to enrollment). F. Adequate hepatic function, as defined by: 1. Serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤ 3× the upper limit of normal. 2. Total bilirubin (T-bil) ≤ 1.5× the upper limit of normal. G. Willingness to refrain from using any other oral probiotics or prebiotics from the first dose of the study intervention ("Synbiotic Supplement" or placebo) through study completion. H. Ability to communicate with study personnel and willingness to comply with study visits, treatment plans, and other trial regulations. Exclusion Criteria: A. Currently pregnant or breastfeeding. B. Received systemic antibiotic therapy for active viral, bacterial, or fungal infections within 2 weeks before the first dose of the study intervention. C. Severe pre-existing medical conditions that, in the investigator's judgment, preclude participation, including but not limited to the following: 1. Severe renal impairment (e.g., estimated creatinine clearance \< 30 mL/min). 2. Interstitial lung disease. 3. Severe dyspnea at rest or the requirement for oxygen therapy. 4. History of major gastrointestinal surgeries, such as gastrectomy or small bowel resection. 5. Pre-existing Crohn's disease, ulcerative colitis, or other chronic conditions that cause clinically significant diarrhea. D. History of the following cardiovascular conditions: syncope of cardiovascular origin, ventricular arrhythmias of pathological origin (including ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: Patients with atrial fibrillation that is controlled and stable for at least 30 days before randomization are eligible. E. Unwillingness or inability to provide written informed consent.

Inclusion Criteria: * Aged 18 years or above * Right-handed * Normal or corrected hearing and vision * Obtained primary education or above * Able to fluently read and understand Chinese * Beck's Depression Inventory-II (BDI-II) score ranging from 14-28 Exclusion Criteria: * History of severe physical disease, brain organic diseases, and neurological disorders (e.g., dementia, brain injury, stroke, epilepsy, Parkinson's disease) * History of substance use/ dependence/ withdrawal * Participants with intellectual disability based on IQ scores * Participants with contraindications for rTMS such as foreign metal bodies, implant devices (cochlear implants) or history (personal or family) of seizure * Participants who are not suitable to be scanned by magnetic resonance imaging (MRI) machine (e.g., claustrophobic, pregnant, metal in the body, hearing aids)

Inclusion Criteria: 1. Male or female participants must be ≥18 years of age. 2. Participants must have received stable doses of ≥3 antihypertensive agents from distinct pharmacological classes for at least 4 weeks prior to signing the ICF, with such therapy maintained until randomization. 3. During the screening period and prior to randomization, SiSBP ≥140 mmHg with or without SiDBP ≥90 mmHg, and SiSBP \<180 mmHg and SiDBP \<110 mmHg. 4. Participants are able to understand and cooperate in completing this trial, voluntarily participate in the trial, and sign the Informed Consent Form (ICF). Exclusion Criteria: 1. Presence of secondary hypertension. 2. Have had transient ischemic attack, stroke, unstable angina pectoris, or acute myocardial infarction occurring within the period from 12 months prior to signing the ICF up to randomization. 3. From screening to prior to randomization, have presence of uncontrolled severe disease or life-threatening disease, or failure to recover from major surgery, or prior thyroid surgery, or presence of malignant tumor, or meeting the criteria for severe hepatic insufficiency at screening. 4. Have had unstable cardiac disease occurring within the period from 6 months prior to signing the ICF up to randomization. 5. Have received dialysis at any time prior to signing the ICF or prior to randomization. 6. Type 1 diabetes. 7. Compliance with any background antihypertensive drug or placebo is \<80% or \>120% during the run-in period. 8. Use of endothelin receptor antagonists, antihypertensive drugs other than background medications, or other blood pressure-affecting drugs, or high-dose loop diuretics from 4 weeks prior to signing the ICF until randomization; or use of oligonucleotide antihypertensive agents within 1 year prior to signing the ICF. 9. Hypersensitivity or suspected hypersensitivity to the excipients of the investigational product, endothelin receptor antagonists, or background antihypertensive drugs, or potential hypersensitivity to the investigational product. 10. Participated in other clinical trials and received at least one dose of study treatment within 12 weeks prior to signing the ICF. 11. Average night shifts are ≥ 2 times per week during the 4 weeks prior to signing the ICF, the screening period, the run-in period, or the anticipated study period. 12. History of drug abuse or alcohol abuse within 5 years prior to signing the ICF. 13. Any of the following test results during the screening period or prior to randomization: 1\) BMI≥37.5 kg/m2. 2) Hemoglobin \< 100 g/L; 3) NT-proBNP ≥ 500 pg/mL; 4) QTcF: \> 450 ms in males, \> 470 ms in females; 5) eGFR \< 15 mL/min/1.73 m²; 6) ALT or AST \> 3 × ULN, or total bilirubin \> 1.5 × ULN; 7) HbA1c \> 8.0%; 8) TSH outside the normal range and FT3 and/or FT4 outside the normal range; 9) Positive HBsAg and positive HBV-DNA, or positive for any of anti-HCV antibody, anti-HIV antibody, anti-Treponema pallidum antibody. 14\. Female participants of childbearing potential who are pregnant, breastfeeding, or have a positive pregnancy test from signing the ICF until randomization; or female participants of childbearing potential and male participants who plan to conceive (including sperm or egg donation) and/or are unable to use effective contraceptive methods during the study period and within 30 days after the end of treatment.

Inclusion Criteria: * Males or females aged 18 to 75 years. * Diagnosis of primary hypertension. * Treatment with either no, or up to 2 antihypertensive medications at a stable dose for at least 4 weeks preceding screening. * Systolic blood pressure ≥140 and \<165 mmHg based on the mean of 3 sitting measurements based on office blood pressure monitoring. * Diagnosis of hypercholesterolemia including heterozygous familial hypercholesterolemia unable to reach LDL-C goals with a stable dose of statin treatment for at least 4 weeks prior to screening as per Investigator judgement, guidelines and local practice (if tolerated and not contraindicated) with or without bempedoic acid and with or without ezetimibe prescribed according to local guidance, at a stable dose for at least 4 weeks preceding Screening Visit 1. The following parameters must be confirmed at Screening Visit 2: * Fasting serum LDL-C ≥70 mg/dL and \<190 mg/dL using Friedewald equation. * Fasting triglyceride \<400 mg/dL. Exclusion Criteria: * Symptomatic orthostatic hypotension. * Treatment with certain medications and/or unable to comply with prohibited medications requirements. Other protocol inclusion/exclusion criteria may apply

Inclusion Criteria: 1. Age: Adults aged 18 to 44 years. 2. Residency: Current legal residents of the United States. 3. Clinical Phenotype: Self-report of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), or Panic Disorder. 4. Medication Stability: If currently prescribed psychotropic medications (e.g., SSRIs, SNRIs, benzodiazepines), the dosage must remain stable with no changes in molecule or quantity for at least 3 months prior to enrollment. 5. Language and Technology: Proficiency in English and access to a smartphone or computer for digital data entry. 6. Financial Commitment: Explicit agreement to the "Citizen Science" model, including payment for discounted testing kits. Kit shipping (both directions) is prepaid by the study. Exclusion Criteria: 1. Use of systemic antibiotics, antifungals, or antivirals within the 8 weeks prior to specimen collection. 2. Regular use of commercial probiotics or concentrated prebiotic supplements within 4 weeks of collection. 3. Frequent use of osmotic or stimulant laxatives, or motility agents, within 4 weeks of collection. 4. Chronic use (\>3 times/week) of NSAIDs, systemic corticosteroids, or high-dose Omega-3 supplementation (\>2g/day) within 4 weeks of enrollment. 5. Use of weight-loss medications or GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) within the 3 months prior to enrollment. 6. Confirmed diagnosis of Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (Crohn's or Ulcerative Colitis), Celiac Disease, or history of major gastric/intestinal resection. 7. Current pregnancy or lactation. 8. Presence of cognitive impairments that preclude the ability to provide informed consent. 9. Individuals undergoing active cancer treatment.

Inclusion Criteria: * Age ≥ 18 years. * Clinical diagnosis of type 2 diabetes mellitus. * Baseline glycated hemoglobin (HbA1c) \>7% and ≤12%. * Initiating treatment with semaglutide (oral or subcutaneous) prescribed by the treating physician according to clinical judgment. Exclusion Criteria: * Pregnancy or lactation at the time of enrollment. * History of severe hypersensitivity or adverse reactions to glucagon-like peptide-1 (GLP-1) receptor agonists. * Contraindications to semaglutide as listed in the product label (e.g., severe gastrointestinal disease, certain endocrine tumors). * Any other serious medical condition that, in the investigator's opinion, may interfere with study participation or data interpretation.

Inclusion Criteria: Adults aged 18 to 65 years. Established diagnosis of type 2 diabetes mellitus documented in the medical record, supported by American Diabetes Association diagnostic criteria on at least one prior occasion. HbA1c 6.8% to 8.2% at screening, measured by an NGSP-certified central laboratory assay; confirmed on a repeat sample if discordant with prior records or if the screening value is at the upper or lower boundary. Body mass index 18.5 to 40.0 kg/m2 at screening. Stable background glucose-lowering therapy for at least 3 months before randomization, restricted to metformin, a DPP-4 inhibitor, and/or an SGLT2 inhibitor, either alone or in combination. Documented body-weight stability, defined as no more than +/-5% or +/-3 kg, whichever is smaller, self-reported body-weight change during the 3 months before screening. Willing and able to provide written informed consent. Willing and able to comply with trial visits, study product use, fasting blood sampling, stool sampling, and the study assessment schedule. Willing to receive standardized lifestyle counselling during the 24-week blinded period and to maintain stable background diabetes management as clinically directed. No systemic antibiotic use within 8 weeks before randomization. No probiotic, prebiotic, synbiotic, or postbiotic supplement use within 8 weeks before randomization. Stable hypertension, dyslipidaemia, and stable thyroid replacement therapy are permitted if medication has been initiated and the dose unchanged for at least 3 months before randomization. Exclusion Criteria: Type 1 diabetes, latent autoimmune diabetes of adults, pancreatogenic diabetes, maturity-onset diabetes of the young, gestational diabetes as the current diagnosis, or any non-type-2 form of diabetes. HbA1c less than 6.8% or greater than 8.2% at screening. Current use of GLP-1 receptor agonists or GLP-1/GIP co-agonists, or use within 12 months before randomization. Current use of basal, prandial, or premixed insulin, or any insulin use within 6 months before randomization. Current use of sulfonylureas or meglitinides, or use within 3 months before randomization. Current use of anti-obesity pharmacotherapy or use within 6 months before randomization, including orlistat, naltrexone/bupropion, phentermine/topiramate, or other agents with a primary anti-obesity indication. Recurrent severe hypoglycaemia or hypoglycaemia unawareness. Planned initiation or dose escalation of glucose-lowering medication, anti-obesity medication, or systemic corticosteroids during the 24-week trial period in the judgment of the treating clinician. History of bariatric surgery at any time. Gastrointestinal surgery other than appendectomy or uncomplicated cholecystectomy. Active inflammatory bowel disease, coeliac disease, microscopic colitis, chronic pancreatitis, malabsorption syndrome, or chronic severe gastrointestinal disease likely to affect absorption or trial adherence. Acute gastroenteritis within 4 weeks before randomization. Colonoscopy bowel preparation within 12 weeks before randomization. Faecal microbiota transplantation within 12 months before randomization. Active or recent malignancy within 6 months, except adequately treated non-melanoma skin cancer. Stage 3b to 5 chronic kidney disease, defined as estimated glomerular filtration rate less than 45 mL/min/1.73 m2. Decompensated liver disease or Child-Pugh class B/C. ALT or AST greater than 3 times the upper limit of normal at screening, unless judged clinically insignificant and approved by the investigator. Known or suspected haemoglobinopathy that materially distorts HbA1c measurement or haemoglobin variant known to interfere with the central laboratory assay. Blood transfusion, significant blood loss greater than 250 mL, or erythropoiesis-stimulating agent therapy within 3 months before randomization. Untreated overt thyroid disease, or thyroid medication initiation or dose change within 3 months before randomization. Use of systemic corticosteroids within 4 weeks before randomization. Use of immunosuppressive medication or biologic/immunomodulatory therapy within 5 half-lives before randomization. Pregnancy or lactation; women of childbearing potential not willing to use effective contraception during the 24-week blinded period. Severe psychiatric illness or cognitive impairment that may compromise informed consent, safety, or adherence. Active eating disorder, defined operationally as a positive SCOFF screen with at least 2 affirmative responses at screening, or clinical diagnosis of anorexia nervosa, bulimia nervosa, or binge-eating disorder. Heavy alcohol use or active substance use disorder. Current very-low-calorie diet, ketogenic diet, medically supervised weight-loss diet, or other highly restrictive diet that excludes major food groups. Current cigarette smoking with intention to attempt cessation during the 24-week trial period; current users of nicotine-replacement or smoking-cessation pharmacotherapy initiated within 3 months before randomization. Participation in another interventional clinical trial within 30 days before screening. Known hypersensitivity or clinically significant intolerance to any component of the active product or placebo. Inability or unwillingness to provide stool samples. Any condition that, in the investigator's opinion, would compromise participant safety or trial integrity.

Inclusion Criteria: * Diagnosis of breast cancer, head and neck cancer (including nasopharyngeal carcinoma) receiving radiotherapy * Age ≥18 years and ≤75 years, any sex * Signed written informed consent * Radiation field skin area can be localized and skin inflammation can be assessed * ECOG performance status 0-1, life expectancy ≥3 months * Adequate major organ function * Fertile patients (both sexes) must use effective medical contraception during the study and for 6 months after the last dose * Willing to comply with follow-up and skin image collection Exclusion Criteria: * Cognitive impairment preventing understanding of the study * Use of antibiotics or antifungals within 1 month * Previous treatment with other bacterial preparations * Participation in other bacterial therapy trials * Any abnormality (e.g., scar, tattoo) in the radiation field that would interfere with assessment * Allergy to probiotics or any component of the study preparation; history of severe allergic reactions (e.g., anaphylaxis, angioedema, respiratory distress, allergic purpura, Arthus reaction) * Use of immunosuppressive drugs * Symptomatic or rapidly progressive central nervous system metastases, extensive lung metastases causing dyspnea, tumor invading major vessels or nerves * Poorly controlled cardiac disease (NYHA class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, clinically significant arrhythmia requiring treatment) * Pregnancy or breastfeeding * Active tuberculosis, bacterial or fungal infection (grade ≥2 per CTCAE), or HIV infection * Substance abuse or psychiatric disorder * Active autoimmune disease or history thereof (exceptions: vitiligo, childhood asthma fully resolved with no intervention in adulthood) * History of alcohol or drug abuse * Planned pregnancy from screening until 12 months after last treatment * Any concomitant condition that, in the investigator's judgment, would compromise patient safety or study completion * Any other condition deemed unsuitable for enrollment by the investigator * Inability to provide written informed consent

Inclusion Criteria: * Pregnant women at 18 years old or above * Singleton pregnancy * Gestational age: ≥20 weeks of gestation * Presenting with suspected PE signs or symptoms: New onset of hypertension. New onset of proteinuria Maternal end-organ dysfunction, Uteroplacental dysfunction: \- Informed and written consent Exclusion Criteria: * Confirmed diagnosis of PE * Confirmed diagnosis of HELLP syndrome * Confirmed diagnosis of a fetal chromosomal or structural abnormality * Visible haematuria * Multiple pregnancies * Patients with pre-existing renal disease * Concomitant participation in another clinical trial * Investigational medicinal product received in the past 3 months (90 days) * Unwilling to give informed consent.

Inclusion Criteria: * Student enrolled at Paris Sciences et Lettres University (PSL, 17,000 students) or the Faculty of Health Sciences at Paris Cité University (UPC, 28,000 students), * Aged 18 or over, * Fluent in French, * Affiliated to a health insurance. Exclusion Criteria: * Applicants under the age of 18, * Not enrolled at PSL universities or the UPCS Faculty of Health, * Insufficient level of French.

Inclusion Criteria: * Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension * Pseudophakic or planned removal of cataract * Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception Exclusion Criteria: * Uncontrolled systemic disease * History of incisional/refractive corneal surgery * Any glaucoma diagnosis other than OHT, open-angle, or pigmentary glaucoma * History of incisional glaucoma surgery * Other ocular diseases, pathology, or conditions

Inclusion Criteria: Patients eligible for inclusion in this study must meet all of the following criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Age ≥ 18 years old. 3. ECOG performance status ≤ 2. 4. Patients with one of the following indications (regardless of lines of prior therapy): Locally advanced unresectable or metastatic PDAC, NSCLC, HR+/HER2- ductal or lobular BC, TNBC, CRC or STS. 5. Patients must have at least one measurable lesion per RECIST v1.1 as measured by local Investigator (by conventional MRI or CT scan). 6. Patients must have an available archival tumor sample at the screening visit. If multiple archival tumor samples are available, the most recent will be requested. Exceptions may be made after documented discussion with Novartis. Exclusion Criteria: Patients meeting any of the following criteria are not eligible for inclusion in this study: 1. Out-of-range laboratory values defined as: * Estimated glomerular filtration rate \< 60 mL/min (calculated using CKD-EPI 2021 formula, or measured based on 24-hour urine collection) * Total bilirubin \> 1.5 x ULN (except for patients with Gilbert's syndrome who are excluded if total bilirubin \> 3.0 x ULN) or direct bilirubin \> 1.5 x ULN * Alanine aminotransferase (ALT) \> 3.0 x ULN, except for patients with tumor involvement of the liver who are excluded if ALT \> 5.0 x ULN * Aspartate aminotransferase (AST) \> 3.0 x ULN, except for patients with tumor involvement of the liver who are excluded if AST \> 5.0 x ULN * Absolute Neutrophil Count \< 1.0 x 109/L * Hemoglobin \< 9 g/dL * Platelet count \< 75 x 109/L 2. Unmanageable urinary tract obstruction or urinary incontinence. If ureteral obstruction can be managed with the placement of ureteral stents, this exclusion criterion does not apply. 3. Known hypersensitivity to 68Ga-DFC413 or 68Ga-NNS309 or their excipients. 4. Any serious uncontrolled infection (acute or chronic), such as, but not limited to, bacterial, viral or fungal infections, confirmed by clinical evidence, imaging, and/or relevant positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA). If a serious infection develops, it must resolve or be adequately controlled prior to 68Ga-DFC413 and/or 68Ga-NNS309 initiation. 5. Surgery or major invasive procedure within 4 weeks prior to 68Ga-DFC413 or 68Ga-NNS309 administration or between the two imaging agents. 6. Radiation therapy within 2 weeks prior to 68Ga-DFC413 or 68Ga-NNS309 administration or between the two imaging agents. 7. Change in anticancer therapy within 2 weeks prior to 68Ga-DFC413 or 68Ga-NNS309 administration or between the two imaging agents. 8. Radiological contrast administration within 48 hours prior to 68Ga-DFC413 or 68Ga-NNS309 administration. 9. Initiation or increasing doses of corticosteroids, TGF-β signaling inhibitors or immunomodulators within 2 weeks prior to 68Ga-DFC413 or 68Ga-NNS309 administration or between the two imaging agents. 10. Known additional malignancy that is progressing or requires active treatment. 11. Inability to complete the required investigational and standard imaging examinations due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time). 12. Presence of CTCAE version 5.0 ≥ Grade 2 toxicity due to prior cancer therapy, except for neuropathy (inclusion of patients with neuropathy of ≤ Grade 2 is permitted) and alopecia. 13. Any medical condition that would, in the Investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures (including radiation safety precautions), or interpretation of study results. 14. Pregnant women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test. 15. Nursing (breast-feeding) women. Women who do not breast feed for 12 hours after 68Ga-DFC413 and/or 68Ga-NNS309 administration, but express and discard breast milk, are eligible. 16. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they use highly effective methods of contraception (failure rate \<1% per year) for 12 hours after the administered radioactive dose of 68Ga-DFC413 and 68Ga-NNS309. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. hormonal profile confirming menopause and/or age-appropriate history of vasomotor symptoms). Highly effective contraception methods include: * Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Note that periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. * Bilateral tubal ligation, female sterilization (have had bilateral oophorectomy with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking 68Ga-DFC413 or 68Ga-NNS309. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment are they considered to be not of childbearing potential. * Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient. * Use of oral (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example, hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent (IC). 17. Sexually active males unwilling to use a condom during intercourse for 12 hours after the administered radioactive dose of 68Ga-DFC413 and 68Ga-NNS309. A condom is required for all sexually active male patients to prevent them from fathering a child and/or to prevent delivery of study treatment via seminal fluid to their partner. In addition, male patients must not donate sperm for the time period specified above. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the IC. Other protocol-defined inclusion/exclusioncriteria may apply.

Inclusion Criteria: 1. Age ≥18 and ≤70 years 2. Histologically confirmed invasive breast cancer, HR+ (ER ≥1% and/or PR ≥1%) and HER2-low (IHC 1+ or IHC 2+/ISH-) 3. No prior systemic anti-tumor therapy for breast cancer 4. Stage II-III (T1cN1-2M0, T2-4N0-2M0) per AJCC 8th edition 5. At least one of the following intermediate-to-high risk factors: * Axillary lymph node involvement ≥1 * Tumor size≥2 cm * Grade 3 tumor * Ki-67 ≥20% 6. At least one measurable lesion per RECIST 1.1 7. ECOG PS 0-1 8. Adequate organ function (ANC ≥1.5×10⁹/L, platelets ≥100×10⁹/L, Hb ≥90 g/L, TBIL ≤1.5×ULN, ALT/AST ≤2.5×ULN, Cr ≤1.5×ULN or CrCl ≥60 mL/min, LVEF ≥50%, QTcF ≤470 ms in females, DLCO ≥50% predicted 9. Negative pregnancy test (for women of childbearing potential) and agreement to use adequate contraception during and for 6 months after treatment 10. Willing and able to provide informed consent and comply with study procedures Exclusion Criteria: 1. Non-pathologically confirmed breast cancer 2. Bilateral, inflammatory, or occult breast cancer 3. Prior anticancer therapy (chemotherapy, radiotherapy, targeted therapy, endocrine therapy, etc.) 4. Concurrent use of other anticancer treatments 5. Other malignancy within 5 years (except cured basal cell carcinoma or cervical carcinoma in situ) 6. Participation in another interventional clinical trial within 4 weeks prior to first dose 7. Use of immunosuppressive agents or systemic corticosteroids (\>10 mg/day prednisone or equivalent) within 2 weeks prior to first dose 8. Live or attenuated vaccine within 4 weeks prior to first dose 9. Major surgery unrelated to breast cancer within 4 weeks prior to first dose 10. Active or history of autoimmune disease requiring systemic treatment 11. Known immunodeficiency (e.g., HIV positivity) or history of organ transplantation 12. Uncontrolled or significant cardiovascular disease (e.g., NYHA class III/IV heart failure, myocardial infarction, unstable angina, arrhythmia requiring treatment, QTcF \>470 ms, uncontrolled hypertension) 13. Known or suspected interstitial lung disease (ILD) or significant pre-existing pulmonary disease 14. Active hepatitis B (HBsAg positive and HBV DNA ≥500 IU/mL) or hepatitis C (HCV RNA above ULN), cirrhosis, or uncontrolled severe infection 15. Known bleeding or thrombotic tendency 16. Allergy or contraindication to any study drug or excipient 17. Pregnancy, breastfeeding, or positive pregnancy test at baseline 18. Any concurrent condition that may compromise patient safety or study compliance (e.g., uncontrolled hypertension, severe diabetes, active infection) 19. History of neurological or psychiatric disorders (e.g., epilepsy, dementia) or any condition deemed unsuitable by the investigator.

Inclusion Criteria: * Histologically confirmed diagnosis of ALK/ROS1-positive non-small cell lung cancer (NSCLC), stage IIIB/IV. * Currently receiving lorlatinib as part of the standard therapeutic regimen. * Documented neurocognitive adverse events (NAEs) attributable to lorlatinib. * Age \>= 18 years. * ECOG performance status 0-2. * Ability to understand and sign informed consent. * Expected survival \>= 6 months. * Planned initiation of vortioxetine as part of standard care. * Ability to complete neuropsychological tests and questionnaires in Spanish. Exclusion Criteria: * Prior diagnosis of major cognitive impairment unrelated to cancer treatment. * Current use of another antidepressant that cannot be discontinued. * Uncontrolled major psychiatric disorder. * History of uncontrolled epilepsy or recent seizures. * Severe hepatic or renal impairment. * Known hypersensitivity to vortioxetine. * Participation in another clinical trial within the past 30 days. * Inability to provide informed consent. * Life expectancy \< 3 months. * Contraindications to vortioxetine (e.g., concomitant MAOI use). * Prior vortioxetine use. * Severe psychiatric disorders or significant cognitive impairment unrelated to lorlatinib.

Inclusion Criteria: * Women aged 18 years or older diagnosed with primary breast cancer who have completed surgical treatment and are scheduled to receive adjuvant radiotherapy. * Patients who will receive radiotherapy for the first time. * Patients whose general health condition is suitable for participation in the study and follow-up assessments. * Patients who are able to read, understand, and communicate in Turkish. * Patients who have access to the internet and are able to use a smartphone, tablet, or computer to access the digital education program. * Patients who voluntarily agree to participate in the study and provide written informed consent. Exclusion Criteria: * Previous radiotherapy to the same treatment area. * Presence of an active infection, open wound, or severe dermatological disease within the radiation treatment field. * History of a chronic skin condition that may affect radiation-induced skin reactions. * Cognitive or psychiatric conditions that may prevent participants from following the educational program or complying with the study procedures and data collection process.

Inclusion Criteria: 1. Aged 18-65 years 2. Diagnosed with primary hypertension (Stage 1 or 2) 3. Systolic blood pressure 130-179 mmHg or diastolic 80-109 mmHg 4. Taking antihypertensive medication 5. Able to understand and communicate in Turkish 6. Willing to provide written informed consent Exclusion Criteria: 1. Secondary hypertension 2. Pregnancy or lactation 3. Severe cardiovascular disease (heart failure, myocardial infarction within 6 months) 4. Stroke history within 6 months 5. Skin lesions or infection at acupressure sites (HT7, LI4, PC6, EX3) 6. Peripheral neuropathy affecting sensation 7. Current use of anticoagulant therapy 8. Participation in another clinical trial within 30 days

Inclusion Criteria: * Young adults aged between 20-35 years, as defined by the WHO. * At risk of diabetes based on self-reported family history or lifestyle habits. * Participants who are willing to engage in the mHealth intervention program. * Own a smartphone and are familiar with using mobile apps. * Complete the informed consent process, agreeing to follow the study protocol, including survey completion and health assessment. Exclusion Criteria: * Individuals diagnosed with chronic mental or physical illnesses * Individuals with hearing or vision loss so severe that they could not access the mobile health intervention. * Pregnant women or women who plan on becoming pregnant during the study. * Individuals who are already taking part in an equivalent diabetes or health programme. * Individuals who are not willing to provide consent.

Inclusion Criteria: * Age between 18 and 60 years * Body Mass Index (BMI) ≥ 35 kg/m² without comorbidities, OR BMI ≥ 30 kg/m² with at least one obesity-related medical comorbidity (e.g., type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia) * Patient is generally fit for laparoscopic surgery and general anesthesia as determined by preoperative evaluation * Patient agrees to comply with postoperative lifestyle changes (dietary modifications and follow-up schedule) * Willing and able to provide written informed consent Exclusion Criteria: * Age \< 18 years or \> 60 years * Inability or unwillingness to adhere to postoperative lifestyle changes * Contraindication to surgery: American Society of Anesthesiologists (ASA) class IV or higher * History of receiving radiotherapy or chemotherapy for cancer treatment * Active substance use disorder or uncontrolled severe psychiatric illness that would impair ability to comply with study procedures (e.g., active psychosis, severe suicidal ideation) * Pregnant or breastfeeding women (pregnancy test performed preoperatively per institutional protocol) * Previous bariatric surgery (revisional surgery excluded) * Untreated thyroid disorder (e.g., hypothyroidism or hyperthyroidism)

Inclusion Criteria: * Age \>18 years * Confirmed diagnosis of primary biliary cholangitis (at least two of the following three criteria must be fulfilled: persistent elevation of alkaline phosphatase above the upper limit of normal for at least 6 months; presence of antimitochondrial antibodies or PBC-specific antinuclear antibodies; characteristic histopathology) * Written informed consent for participation in the registry Exclusion Criteria: * Withdrawal of written informed consent

Inclusion Criteria: * 18 years or older * Able to read and speak in English * Able to understand the nature of the study and able to provide written informed consent * Current major depressive episode of at least 2 weeks duration as assessed by the Structured Clinical Interview for DSM-5 (SCID) and a Patient Health Questionnaire - 8 (PHQ-8) score of 10 or greater at screening * Willing to use a form of pregnancy contraceptive (e.g., barrier methods such as condoms, oral contraception, or other birth control type) if assigned female sex at birth and premenopausal * Able to lie supine for 2 hours in a sauna device * Access to the internet via computer, smartphone, or tablet Exclusion Criteria: * \>30% reduction in BDI-II score between Screen #1 and Screen #2 (conducted \~1 week after Screen #1) * Suicide attempt in the past 12 months defined using the SAMHSA suicidality question during the clinician-administered interview or active suicidal ideation as indexed by a score of 3 on the BDI-II suicidality item during the clinician-administered interview * Any of the following medical conditions: cardiovascular disease (other than controlled hypertension), seizure disorder, history of cerebrovascular accident (CVA) or other serious neurological condition (e.g. Parkinson's disease, multiple sclerosis, or dementia), current neoplasia, any active enclosed infection (e.g. dental abscess, joint infection), hemophilia or other cause for excessive bleeding (e.g. platelet disorder), or other medical condition that in the opinion of investigators may increase the risk of WBH * Comorbid psychiatric conditions or history of comorbid psychiatric conditions that might better explain depressive symptoms, including schizophrenia, schizoaffective disorder, Bipolar Disorder I, Obsessive Compulsive Disorder, Anorexia Nervosa, Bulimia Nervosa, Alcohol Dependence, or Drug Dependence * Known hypersensitivity to hyperthermia and/or infrared exposure * Inability to fit into the sauna device * Breast implants * Pregnancy, active lactation or intention to become pregnant during the study period * Use of any medication that might impact thermoregulatory capacity, including: Diuretics, barbiturates, beta-blockers, antipsychotic agents, anti-cholinergic agents or chronic use of antihistamines, aspirin (other than low-dose ASA for prophylactic purposes), medication prescribed for the treatment of depression (antidepressant medication \[ADM\]) including but not limited to: selective serotonin reuptake inhibitors \[SSRIs\], Serotonin and norepinephrine reuptake inhibitors \[SNRIs\], Monoamine oxidase inhibitors \[MAOIs\], Tricyclics \[TCAs\], and atypical antipsychotic and antidepressant medications (participants must have been free of these medications for at least 4 weeks), antibiotics (past 14 days), pain medication (opioids) due to procedure, e.g., dental procedure (past 14 days), Emergency contraception pill (past 14 days), or any other medication that in the judgment of the PI would increase risk of study participation or introduce excessive variance into physiological or behavioral responses to WBH * Recent use (multiple consecutive doses) of: non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids, cytokine antagonists * Regular use of any nicotine products, including cigarettes, vapes, chewing tobacco, or other forms of nicotine (if use is not regular, must be willing to refrain for 24 hours before and 24 hours after WBH session) * Unwilling to refrain from using marijuana products and alcohol for the 24 hours before and 24 hours after WBH session * Unwilling to refrain from heavy exercise on the day of WBH sessions * Unwilling to refrain from engaging with sauna, hot yoga, cold plunges, cryotherapy, and hot tub/jacuzzi outside of study (prospective participant must not have engaged with any of these activities for 30 days prior to their baseline study visit). * Has begun new psychotherapy treatment in the prior 6 weeks